Dabrafenib-associated necrobiotic granulomatous reaction.
Department of Dermatology, Westmead Hospital, Sydney, New South Wales, Australia; Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia.
Giuliana
G
Carlos
Rachael
R
Anforth
Shaun
S
Chou
Pablo
P
Fernandez-Peñas
D000970:Antineoplastic Agents / Q000009:adverse effects*; D003875:Drug Eruptions / Q000209:etiology; D005260:Female; D016460:Granuloma Annulare / Q000139:chemically induced*; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects*; D008545:Melanoma / Q000188:drug therapy* / Q000235:genetics / Q000556:secondary; D008875:Middle Aged; D010091:Oximes / Q000009:adverse effects*; D048493:Proto-Oncogene Proteins B-raf / Q000235:genetics; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology
D000970:Antineoplastic Agents; D007093:Imidazoles; D010091:Oximes; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf; C561627:dabrafenib